Board of Directors

Jack Davis - Chairman
Mr. Davis was appointed as Chairman of Asterand in May 2008. He was previously on the Board of Asterand prior its merger with Pharmagene plc. He also serves on the boards of Cytologix, Inc., Repromedix (Chairman), Claros, Inc., Collages.net, Inc. and Laboratory Partners, Inc. Mr. Davis co-founded Dianon Systems, a company that specializes in providing pathology services, holding the position of CEO, Chairman and Director. He has also served as CEO and director of Calpyte Biomedical Corporation, Genica Pharmaceuticals and Infant Advantage, Inc. For over 15 years, Mr. Davis served in various executive positions with Abbott Laboratories, the last being Vice President and General Manager of Worldwide Diagnostic Products.

Martyn Coombs - Chief Executive Officer
Martyn Coombs was appointed as Chief Executive Officer and Director of Asterand plc in March 2007. Prior to joining Asterand, Mr. Coombs worked for Amersham plc for nine years in various senior roles. He led global logistics during Amersham's period of rapid growth and merger activity in which the company's revenue trebled in size to £1.4 billion. Subsequently he served in Japan for five years as President Amersham KK and concurrently Executive Vice President of Nihon Medi-Physics Co. Ltd, a $300m revenue Joint Venture between Amersham and Sumitomo Chemical. Mr Coombs served on the Board of Nihon Medi-Physics Co. Ltd as Amersham's only Executive Director. Mr. Coombs has also served as President of PerkinElmer Japan, a subsidiary of PerkinElmer, Inc. He holds a degree in Mathematics and an MBA from Warwick Business School.

Dr. Peter Coggins - Non-Executive Director
Dr. Coggins was appointed as a Non-Executive Director of Asterand plc in April 2008. Mr. Coggins has thirty-five years experience in the biotechnology and life science industry. Previously he was President of PerkinElmer Inc. Life and Analytical Sciences, and as such had full p&l responsibility for a business with sales of $1.2 billion and staff of 4,200. In this capacity he also served as a Corporate Officer and a member of the Executive Committee. Prior to PerkinElmer, Dr. Coggins served as Executive VP Global Sales, at Amersham Biosciences. Dr. Coggins is a past Chairman of ALSSA (Analytical & Life Science Sciences Association), an advisory committee member to the U.S. Secretary of Health and Human Services, and is currently a Director on the Boards of Biohit Ovi (Helsinki) and deltaDOT Ltd (London). Dr. Coggins holds a first degree and a Ph.D. in Zoology from Chelsea College, University of London.

Jonathan Fleming - Non-Executive Director
Mr. Fleming was appointed as a Non-Executive Director of Asterand plc in September 2008. Since 1996, he has been a General Partner of Oxford Bioscience Partners and currently serves as the Managing General Partner. Oxford Bioscience Partners is an international venture capital firm with more than $ 900 million under management that specializes in life science technology based investments. Prior to joining Oxford Bioscience Partners, Mr. Fleming was a founding General Partner of MVP Ventures (Boston, MA) and a co-founder of Medica Venture Partners (Israel). He currently serves as a Director on the Boards of Memory Pharmaceuticals Corp (Montvale, NJ), Leerink Swann Investment Trust (Boston, MA), RailRunner NA Corp (Lexington, MA) and BioProcessors Corp (Woburn, MA). Mr. Fleming holds a BA from the University of California, Berkeley and a MPA from Princeton University.

Jill L. Force - Non-Executive Director
Ms. Force was appointed as a Non-Executive Director of Asterand plc in June 2008. Ms. Force is currently a Partner with The Allegro Group, Inc. (Louisville, KY) which provides interim management and business advisory services to public and private healthcare companies as well as equity and venture capital firms. Prior to this position, she served as Executive Vice President, General Counsel and Chief Administrative Officer for Life-Care, a privately held company that operates 20 long term acute care hospitals. Ms. Force spent 10 years as SVP, General Counsel and Corporate Secretary for Vencor, Inc. (now Kindred Healthcare, Inc.) where she was part of a team that grew the company from one hospital to a Fortune 500 operator of hospitals, nursing facilities and contract medical services. Ms. Force is a certified public accountant and an attorney with a degree in Political Science from Miami University, a Master of Science in Accounting from Georgetown University and a Juris Doctorate from University of Louisville School of Law.

Ian Ratcliffe - Non-Executive Director
Mr. Ratcliffe was appointed as a Non-Executive Director of Asterand plc in May 2008 . He is currently President and CEO of Stemgent Inc. a Boston, MA based research products company, focused on the development and sale of novel consumable reagents for use in stem cell research. Prior to Stemgent, Mr. Ratcliffe was President of Upstate, a leading provider of cell signaling research products and services. He also previously served as the Company?s COO, CFO and EVP of Sales and Marketing. In his final post as President, Mr. Ratcliffe was instrumental in facilitiating the acquisition of Upstate by Serologicals Corp. in September 2004 and he served as President of the Upstate division until May 2005. Trained as a chemical engineer, Mr. Ratcliffe also worked for several prominent engineering firms including Matthew Hall Engineering, and Chemnique, Ltd., which he founded in 1989.

Mr. Ratcliffe is Chairman of Enzymatics (Boston), a manufacturer of molecular biology reagents, and a Director of Global Cell Solutions (Charlottesville, VA), a biotech firm commercializing proprietary 3D cell culture technology. Mr. Ratcliffe earned his first degree in Chemical Engineering from University of Surrey Guilford, Surrey, England and an M.B.A. from the Darden Graduate School of Business Administration at the University of Virginia.

Robert Salisbury - Non-Executive Director
Mr. Salisbury was appointed as a Non-Executive Director of Asterand plc in June 2008. Mr. Salisbury has more than 20 years of experience in the pharmaceutical industry. Previously, he was Executive Vice President & Chief Financial Officer of Pharmacia & Upjohn Inc (Windsor UK) and as such had full responsibility for the finance, corporate strategy, human resources, investor relations & corporate communication functions within the company. In this capacity, he was integral to implementation of the post-merger global integration of the two companies across its units and subsidiaries within 48 countries. Mr. Salisbury has extensive investor contacts through his involvement in Pharmacia?s $4 billion secondary stock offering and other investor relations activities. Mr. Salisbury has a degree in Finance and an M.B.A. from Florida State University. Mr. Salisbury is currently a Director and Chair of the Audit Committee at Enzon Pharmaceuticals Inc (Bridgewater, NJ).